immunologic adjuvants

Summary

Summary: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Top Publications

  1. ncbi Molecular identification of a danger signal that alerts the immune system to dying cells
    Yan Shi
    Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Nature 425:516-21. 2003
  2. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
  3. ncbi Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
    Sandra L Giannini
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Vaccine 24:5937-49. 2006
  4. ncbi Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
    Stephanie C Eisenbarth
    Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Nature 453:1122-6. 2008
  5. ncbi The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4
    Veronica Mata-Haro
    Institute for Cellular Therapeutics, University of Louisville, 570 South Preston Street, Louisville, KY 40202, USA
    Science 316:1628-32. 2007
  6. ncbi Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release
    Hanfen Li
    Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA
    J Immunol 178:5271-6. 2007
  7. ncbi Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
    Hiroaki Hemmi
    Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, 3 1 Yamada oka, Suita, Osaka 565 0871, Japan
    Nat Immunol 3:196-200. 2002
  8. pmc Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity
    Matthias Tenbusch
    Department of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany
    BMC Immunol 9:13. 2008
  9. ncbi Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling
    J M Brewer
    Department of Immunology, University of Glasgow, Western Infirmary, Scotland, United Kingdom
    J Immunol 163:6448-54. 1999
  10. ncbi Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice
    Unni C Nygaard
    Division of Environmental Medicine, Norwegian Institute of Public Health, NO 0403 Oslo, Norway
    Toxicol Sci 109:113-23. 2009

Detail Information

Publications284 found, 100 shown here

  1. ncbi Molecular identification of a danger signal that alerts the immune system to dying cells
    Yan Shi
    Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Nature 425:516-21. 2003
    ..Our findings provide a molecular link between cell injury and immunity and have important implications for vaccines, autoimmunity and inflammation...
  2. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
    ....
  3. ncbi Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
    Sandra L Giannini
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Vaccine 24:5937-49. 2006
    ..These data strongly support the role of the AS04 adjuvant, which includes the immunostimulant MPL, in triggering a persistent vaccine-induced immune response of high quality...
  4. ncbi Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
    Stephanie C Eisenbarth
    Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Nature 453:1122-6. 2008
    ..This is likely to affect how we design effective, but safe, adjuvants in the future...
  5. ncbi The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4
    Veronica Mata-Haro
    Institute for Cellular Therapeutics, University of Louisville, 570 South Preston Street, Louisville, KY 40202, USA
    Science 316:1628-32. 2007
    ..This finding may have important implications for the development of future vaccine adjuvants...
  6. ncbi Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release
    Hanfen Li
    Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA
    J Immunol 178:5271-6. 2007
    ..Considering the immunostimulatory activities of these cytokines and the ability of IL-1beta to act as adjuvant, our results suggest a mechanism for the adjuvanticity of Alum...
  7. ncbi Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
    Hiroaki Hemmi
    Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, 3 1 Yamada oka, Suita, Osaka 565 0871, Japan
    Nat Immunol 3:196-200. 2002
    ..Imidazoquinoline-induced signaling events were also abolished in both MyD88- and TLR7-deficient mice...
  8. pmc Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity
    Matthias Tenbusch
    Department of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany
    BMC Immunol 9:13. 2008
    ..In addition, bicistronic vectors allowing independent expression of the antigen and the cytokine were tested in parallel...
  9. ncbi Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling
    J M Brewer
    Department of Immunology, University of Glasgow, Western Infirmary, Scotland, United Kingdom
    J Immunol 163:6448-54. 1999
    ..We conclude that alum adjuvants can induce IL-4 production and Th2 responses independently of IL-4 or IL-13, negating the requirement for an early source of IL-4 in the Th2 response induced by this adjuvant...
  10. ncbi Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice
    Unni C Nygaard
    Division of Environmental Medicine, Norwegian Institute of Public Health, NO 0403 Oslo, Norway
    Toxicol Sci 109:113-23. 2009
    ..This study demonstrates that CNTs promote allergic responses in mice...
  11. pmc Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
    Mirjam Kool
    Department of Pulmonary Medicine, Erasmus University Medical Centre, 3015 GD Rotterdam, Netherlands
    J Exp Med 205:869-82. 2008
    ..These findings suggest that alum adjuvant is immunogenic by exploiting "nature's adjuvant," the inflammatory DC through induction of the endogenous danger signal uric acid...
  12. ncbi New horizons in adjuvants for vaccine development
    Steven G Reed
    Infectious Disease Research Institute, 1124 Columbia St Suite 400, Seattle, WA 98104, USA
    Trends Immunol 30:23-32. 2009
    ..In this review, we outline the current state of adjuvant research and development and how formulation parameters can influence the effectiveness of adjuvants...
  13. ncbi IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses
    Carola Schellack
    Intercell AG, Campus Vienna Biocenter 6, 1030 Wien, Austria
    Vaccine 24:5461-72. 2006
    ..Activation of murine dendritic cells by IC31 induced efficiently proliferation of naïve CD4(+) TCR transgenic T cells (DO.11.10) as well as their differentiation into IFN-gamma- and IL-4-producing T cells in vitro...
  14. ncbi Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults
    Daniel Wai Sing Chu
    Dept of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong
    Vaccine 27:7428-35. 2009
    ..These characteristics make it suitable for presumptive use if an H5N1 pandemic were considered to be imminent...
  15. ncbi A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant
    Allan Saul
    The Cooperative Research Centre for Vaccine Technology, Brisbane, QLD, Australia
    Vaccine 23:3076-83. 2005
    ..Six of the 29 subjects seroconverted. Only one of these developed a high antibody titre. However, the interpretation of this trial was compromised by a loss of potency of the formulated vaccine during the course of the study...
  16. ncbi The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu
    Mohamed L Salem
    Department of Surgery, Section of Surgical Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    Vaccine 24:5119-32. 2006
    ..We conclude that the adjuvant effects of poly (I:C) on antigen-specific CD8(+) T cells appeared to be exquisitely dependent on the rapid induction of certain beneficial cytokines produced in part by NK cells...
  17. ncbi SEPPIC vaccine adjuvants for poultry
    L Dupuis
    SEPPIC, 75 quai d Orsay, 75321 Paris, Cedex 07, France
    Ann N Y Acad Sci 1081:202-5. 2006
    ..Results show that it is possible to improve traditional Tween Span formulations for safety and efficacy parameters by using Montanide ISA 70 for W/O formulations and Montanide ISA 206 for W/O/W when safety is the priority...
  18. ncbi Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
    ..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response...
  19. ncbi Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum
    J Poot
    Intervet International B V, Parasitology R and D, Wim de Korverstraat 35, 5831AN Boxmeer, The Netherlands
    Vaccine 24:2460-8. 2006
    ..More plausible explanations are the dose and timing of the IL-12 application and the potentially different effects IL-12 induces as an adjuvant in either the murine or the canine leishmaniosis model...
  20. pmc Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
    Silvia B Boscardin
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 203:599-606. 2006
    ..We conclude that antigen targeting to DCs combined with a maturation stimulus produces broad-based and long-lived T cell help for humoral immune responses...
  21. ncbi Vaccines for seasonal and pandemic influenza
    Kristin L Nichol
    University of Minnesota and Minneapolis VA Medical Center, Minneapolis, MN, USA
    J Infect Dis 194:S111-8. 2006
    ..Additional experimental approaches are required to achieve the ultimate goal for seasonal and pandemic influenza prevention--namely, the ability to generate broadly cross-reactive and durable protection in humans...
  22. ncbi The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome
    Mahmoud R Jaafari
    School of Pharmacy, Biotechnology Research Center and Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
    Vaccine 25:6107-17. 2007
    ..The results indicate that co-encapsulation of CpG ODN in liposomes improves the immunogenicity of Leishmania antigen...
  23. ncbi Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial
    Hans C Rumke
    Vaxinostics BV, University Vaccine Center Rotterdam Nijmegen, Beursplein 37, PO Box 30142, 3001 DC Rotterdam, The Netherlands
    Vaccine 26:2378-88. 2008
    ..The safety and reactogenicity profile of the AS-H5N1 candidate vaccine can be considered clinically acceptable in the context of its use against pandemic influenza...
  24. ncbi Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 168:562-8. 2002
    ..These results demonstrate that bicistronic DNA vaccines containing GM-CSF elicit remarkably potent CD4(+) T cell responses and suggest that optimal Th cell priming requires the precise temporal and spatial codelivery of Ag and GM-CSF...
  25. pmc Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements
    Else Marie Agger
    Adjuvant Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    PLoS ONE 3:e3116. 2008
    ..The development of new adjuvants capable of inducing highly complex immune responses with strong antigen-specific T-cell responses in addition to antibodies is therefore urgently needed...
  26. pmc A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity
    Shee Eun Lee
    National Research Laboratory of Molecular Microbial Pathogenesis and Department of Microbiology, Chonnam National University Medical School, 5 Hak dong, Dong Ku, Gwangju 501 746, South Korea
    Infect Immun 74:694-702. 2006
    ..These results indicate that flagellin would serve as an efficacious mucosal adjuvant inducing protective immune responses through TLR5 activation...
  27. pmc Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques
    Christiane Stahl-Hennig
    Laboratory of Infection Models, German Primate Center, Gottingen, Germany
    PLoS Pathog 5:e1000373. 2009
    ..Thus, synthetic dsRNAs induce an innate chemokine response and act as adjuvants for virus-specific Th1 and humoral immune responses in nonhuman primates...
  28. ncbi Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro
    Garry L Morefield
    Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, Room 124, West Lafayette, IN 47907 2051, USA
    Vaccine 23:1588-95. 2005
    ....
  29. pmc Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
    M Paula Longhi
    Laboratory of Cellular Physiology and Immunology and Chris Browne Center, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 206:1589-602. 2009
    ..Therefore, the adjuvant action of poly IC requires a widespread innate type I IFN response that directly links antigen presentation by DCs to adaptive immunity...
  30. pmc 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Nucleic Acids Res 30:4460-9. 2002
    ..These results suggest that immunomers have several advantages over conventional linear CpG DNAs for immunomodulatory activity studies...
  31. ncbi CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants
    G B Lipford
    Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Germany
    Eur J Immunol 27:2340-4. 1997
    ..Thus ssDNA oligomers may serve as inexpensive and safe vaccine adjuvants and, in addition, differential effects due to sequence may allow for directed responses...
  32. ncbi ISCOMs and ISCOMATRIX
    Hong Xiang Sun
    Key Laboratory of Animal Epidemic Etiology and Immunological Prevention of Ministry of Agriculture, College of Animal Sciences, Zhejiang University, Kaixuan Road 268, Hangzhou 310029, Zhejiang, China
    Vaccine 27:4388-401. 2009
    ..The mechanisms of adjuvanticity are also discussed in the light of recent findings...
  33. ncbi Toll-like receptors as adjuvant receptors
    Tsuneyasu Kaisho
    Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
    Biochim Biophys Acta 1589:1-13. 2002
    ..Understanding the TLR system should offer invaluable opportunity for manipulating host immune responses...
  34. ncbi Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
    Marion Jurk
    Nat Immunol 3:499. 2002
  35. ncbi Vaccine adjuvants revisited
    J C Aguilar
    Division of Vaccines, Center for Genetic Engineering and Biotechnology, P O Box 6162, La Habana 10600, Cuba
    Vaccine 25:3752-62. 2007
    ..The mechanisms of adjuvanticity are also discussed in the light of recent findings on Toll-like receptors' biology and their involvement on immune activation...
  36. ncbi Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN)
    G P Borja-Cabrera
    Instituto de Microbiologia, Prof Paulo de Góes, Universidade Federal do Rio de Janeiro UFRJ, CCS, Cidade Universitaria, Ilha do Fundao, Caixa Postal 68040, CEP 21941 590, Brazil
    Vaccine 20:3277-84. 2002
    ..Higher seropositivities and intradermal reactions with no Leishmanial DNA were detected in vaccinees. The FML-QuilA vaccine induced a significant, long lasting and strong protective effect against canine kala-azar in the field...
  37. pmc gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani
    Swati Bhowmick
    Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Kolkata 700032, India
    Infect Immun 76:1003-15. 2008
    ..Our results demonstrated that stable cationic liposomes containing gp63 acted as a potent adjuvant for protein antigen to induce long-term protection against L. donovani that represents an alternative to DNA vaccination...
  38. pmc Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse
    Krystyna Mozdzanowska
    Immunology Program, The Wistar Institute, Philadelphia, USA
    Virol J 4:118. 2007
    ....
  39. pmc Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
    Sylvia Adams
    Department of Medicine, Division of Medical Oncology, New York University Cancer Institute, School of Medicine, New York, NY 10016, USA
    J Immunol 181:776-84. 2008
    ..Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity...
  40. pmc Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3
    Hanfen Li
    Department Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA
    J Immunol 181:17-21. 2008
    ....
  41. ncbi In vivo dynamics of an immune response in the bumble bee Bombus terrestris
    P Korner
    Ecology and Evolution, ETH Zentrum NW, 8092 Zurich, Switzerland
    J Invertebr Pathol 87:59-66. 2004
    ..Antibacterial activity, on the other hand, increased sharply between 2 and 24h post-challenge followed by a slow decrease. Surprisingly, the effects of a challenge lasted up to 14 days...
  42. ncbi Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection
    Laura Bungener
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, Postbus 30 001, 9700 RB Groningen, The Netherlands
    Vaccine 26:2350-9. 2008
    ..Major difference between these groups of mice was the type of immune response induced, TH2 instead of TH1, indicating that a TH1 response plays a major role in viral clearance...
  43. pmc Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid
    David H Cribbs
    Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, USA
    Int Immunol 15:505-14. 2003
    ....
  44. ncbi Use of CpG oligodeoxynucleotides as immune adjuvants
    Dennis M Klinman
    Section of Retroviral Immunology, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunol Rev 199:201-16. 2004
    ..Ongoing clinical studies indicate that CpG ODNs are safe and well tolerated when administered as adjuvants to humans, and in some cases, they increase vaccine-induced immune responses...
  45. ncbi Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria
    Maarten L van Roosmalen
    BiOMaDe Technology Foundation, Nijenborgh 4, 9747 AG Groningen, The Netherlands
    Methods 38:144-9. 2006
    ..The GEM-based vaccines do not require additional adjuvant for eliciting high levels of specific antibodies in mucosal and systemic compartments...
  46. ncbi Archaeosome adjuvants: immunological capabilities and mechanism(s) of action
    Lakshmi Krishnan
    National Research Council Institute for Biological Sciences, Ottawa, ON, Canada K1A 0R6
    Vaccine 26:2043-55. 2008
    ....
  47. ncbi Alum adjuvanticity: unraveling a century old mystery
    Ennio De Gregorio
    Department of Immunology, Novartis Vaccines and Diagnostics, Siena, Italy
    Eur J Immunol 38:2068-71. 2008
    ..Surprisingly, these three studies reported conflicting results on the requirement of the Nlrp3 inflammasome complex for alum adjuvant effects in vivo. This commentary attempts to resolve some of these discrepancies...
  48. ncbi Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer
    Andreas Bohle
    Department of Urology, HELIOS Agnes Karll Hospital, Am Hochkamp 21, 23611 Bad Schwartau, Germany
    J Urol 170:964-9. 2003
    ..BCG is regarded as the most successful immunotherapy to date. However, the mode of action has not yet been fully elucidated. We provide a thorough overview of this complex field of research...
  49. ncbi Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins
    Osamu Takeuchi
    Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
    J Immunol 169:10-4. 2002
    ..Taken together, TLR1 interacts with TLR2 to recognize the lipid configuration of the native mycobacterial lipoprotein as well as several triacylated lipopeptides...
  50. pmc Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines
    Gloria Gonzalez-Aseguinolaza
    Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY 10010, USA
    J Exp Med 195:617-24. 2002
    ..As alpha-GalCer stimulates both human and murine NKT cells, these findings should contribute to the design of more effective vaccines against malaria and other intracellular pathogens, as well as tumors...
  51. pmc Mucosal adjuvant activity of flagellin in aged mice
    John T Bates
    Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Mech Ageing Dev 129:271-81. 2008
    ..Our findings are consistent with the conclusion that flagellin can promote adaptive immune responses in aged mice, but at a less robust level than in young mice...
  52. ncbi A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants
    Kohtaro Fujihashi
    Department of Microbiology, BBRB Room 716, Immunobiology Vaccine Center, University of Alabama at Birmingham, Medical Center, 35294 2170, USA
    Vaccine 20:2431-8. 2002
    ..When mucosal adjuvanticity of CT was evaluated in aged mice, an early immune dysregulation was evident in the mucosal immune system. The present review discusses these potential problems for effective mucosal vaccine development...
  53. ncbi Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation
    Stanley L Hem
    Purdue University, Industrial and Physical Pharmacy Department, West Lafayette, IN 47907, USA
    Expert Rev Vaccines 6:685-98. 2007
    ....
  54. pmc The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine
    Christine Trumpfheller
    Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:2574-9. 2008
    ..We suggest that poly IC be tested as an adjuvant with DC-targeted vaccines to induce numerous multifunctional CD4(+) Th1 cells with proliferative capacity...
  55. ncbi Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
    ....
  56. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  57. ncbi Toll or toll-free adjuvant path toward the optimal vaccine development
    Ken J Ishii
    Exploratory Research for Advanced Technology ERATO, Japan Science and Technology Agency JST, Osaka University, Suita, Osaka 565 0871, Japan
    J Clin Immunol 27:363-71. 2007
    ..To develop optimal vaccines, it will be critical to understand how TLR-dependent and TLR-independent innate immune activation, by various adjuvants, control the consequent adaptive immune responses to vaccine...
  58. ncbi TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis
    Klaus Peter Wandinger
    Institute of Neuroimmunology, Charite University Hospital, Schumannstrasse 20 21, 10117, Berlin, Germany
    Lancet 361:2036-43. 2003
    ..We aimed to assess the functional relevance of tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), which is upregulated on incubation with interferon beta, for clinical treatment response...
  59. pmc The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity
    Luigi Franchi
    Department of Pathology and Comprehensive Cancer Center, The University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Eur J Immunol 38:2085-9. 2008
    ..These results indicate that alum induces IL-1beta via the Nlrp3 inflammasome but this activity is dispensable for alum-mediated adjuvant activity...
  60. ncbi Mucosal immunity and vaccines
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute, Goteborg University, SE 405 30 Goteborg, Sweden
    Nat Med 11:S45-53. 2005
    ..Here we review the properties of the mucosal immune system and discuss advances in the development of mucosal vaccines for protection against infections and for treatment of various inflammatory disorders...
  61. ncbi Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation
    P Kalinski
    Academic Medical Center, Department of Cell Biology and Histology, University of Amsterdam, The Netherlands
    J Immunol 161:2804-9. 1998
    ..These data imply that the character of pathogen-induced local inflammatory reaction can "instruct" local DC to initiate Th1 or Th2-biased responses...
  62. ncbi The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
    Anja Seubert
    Novartis Vaccines, Siena, Italy
    J Immunol 180:5402-12. 2008
    ....
  63. ncbi Adjuvant effects of inhaled mono-2-ethylhexyl phthalate in BALB/cJ mice
    Jitka Stilund Hansen
    Airway Allergy and Irritation Group, National Research Centre for the Working Environment, Lersø Parkallé 105, DK 2100 Copenhagen, Denmark
    Toxicology 232:79-88. 2007
    ..03 mg/m(3) MEHP observed in the present study and estimated human exposure levels...
  64. ncbi Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis
    R X Armijos
    Health Sciences Program, College of Health Sciences, University of Texas at El Paso, Room 705, 1101 North Campbell Street, El Paso, TX 79902 0581, USA
    Vaccine 22:1320-6. 2004
    ..0%) and placebo groups (2.0% versus 1.3%; P > 0.05). LST conversion was not associated with CL protection and the vaccine did not offer significant protection against CL infection caused by L. Viannia spp. compared to placebo...
  65. ncbi New vaccines require potent adjuvants like AFPL1 and AFCo1
    O Perez
    Immunology Department, Finlay Institute, Havana City, Cuba
    Scand J Immunol 66:271-7. 2007
    ..Both are very promising adjuvants...
  66. pmc Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge
    Anna U Bielinska
    Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0648, USA
    Infect Immun 75:4020-9. 2007
    ..This potentially could lead to a needle-free anthrax vaccine requiring fewer doses and having fewer side effects than the currently available human vaccine...
  67. pmc Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
    ....
  68. ncbi Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina
    W Min
    Parasite Biology, Epidemiology, Systematics Laboratory, Animal and Natural Resources Institute, BARC-East, Building 1040, US Department of Agriculture, Beltsville, MD 20705, USA
    Vaccine 20:267-74. 2001
    ..These results indicate that the type and the dose of cytokine genes injected into chickens influence the quality of the local immune response to DNA vaccination against coccidiosis...
  69. pmc An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells
    Xiao Tong Song
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
    PLoS Med 3:e11. 2006
    ..Here we tested an alternative strategy to induce anti-HIV immune responses by inhibiting a host's natural immune inhibitor...
  70. ncbi MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Expert Rev Vaccines 6:699-710. 2007
    ..MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types...
  71. pmc The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism
    M Ulanova
    Department of Clinical Immunology, Goteborg University, S 41346 Goteborg, Sweden
    Infect Immun 69:1151-9. 2001
    ..The increase in the expression of antigen-presenting and costimulatory molecules leads to enhanced accessory functions of monocytes. These properties of aluminum hydroxide observed in vitro may explain its potent in vivo adjuvant effect...
  72. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  73. ncbi Low-dose intraperitoneal Freund's adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide
    Jon Oscherwitz
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA
    Vaccine 24:3018-25. 2006
    ..p., the accompanying toxicity remains significant, and thus alternative adjuvants and/or routes should be considered...
  74. ncbi How do adjuvants work? Important considerations for new generation adjuvants
    Amy S McKee
    HHMI, Integrated Department of Immunology, National Jewish Medical and Research Center, University of Colorado Health Science Center, Denver, CO 80262, USA
    Immunity 27:687-90. 2007
    ..In this Commentary, McKee et al. highlight the properties of extrinsic vaccine adjuvants that must be considered to achieve the most protective immune response, as occurs naturally with many intrinsic pathogen-derived adjuvants...
  75. ncbi Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients
    Rosalie M Luiten
    Clinical Immunotherapy, Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 23:8978-91. 2005
    ..To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients...
  76. ncbi Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions
    Pedro Redondo
    Department of Dermatology, University Clinic of Navarra, Pamplona, Navarra, Spain
    J Invest Dermatol 127:1673-80. 2007
    ..These preclinical data and the simplicity of the procedures warrant the design of a pilot clinical trial...
  77. ncbi Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies
    John Geisse
    Solano Dermatology Associates, Vallejo, CA 94589, USA
    J Am Acad Dermatol 50:722-33. 2004
    ..Imiquimod has been shown to be efficacious as a topical treatment for basal cell carcinoma (BCC)...
  78. pmc Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection
    Linda J Berry
    Discipline of Immunology and Microbiology, School of Biomedical Science, The University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales, Australia
    Infect Immun 72:1019-28. 2004
    ..This immunization protocol resulted in enhanced clearance of C. muridarum (C. trachomatis, mouse pneumonitis strain) following intravaginal challenge of BALB/c mice...
  79. ncbi Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome
    Mirjam Kool
    Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    J Immunol 181:3755-9. 2008
    ..We propose that, in addition to TLR stimulators, agonists of the NALP3 inflammasome should also be considered as vaccine adjuvants...
  80. ncbi Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma
    C M Hawrylowicz
    Department of Asthma, Allergy and Respiratory Science, Guy s Hospital, King s College London, London SE1 9RT, UK
    Nat Rev Immunol 5:271-83. 2005
    ..Current research strategies seek to exploit these observations to improve the generation of allergen-specific regulatory T-cell populations with the potential to provide the safe and long-term alleviation of disease symptoms...
  81. ncbi Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type
    Anne Cécile Rimaniol
    SPI Bio, c o Service de Neurovirologie, 92265 Fontenay aux Roses Cedex, France
    Vaccine 22:3127-35. 2004
    ....
  82. ncbi Hypertonic saline resuscitation: a tool to modulate immune function in trauma patients?
    W G Junger
    Department of Surgery, University of California San Diego 92103 8236, USA
    Shock 8:235-41. 1997
    ....
  83. ncbi Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes
    C L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, 22908, USA
    Clin Cancer Res 7:3012-24. 2001
    ..Although this Phase I study was not intended to evaluate clinical benefit, the excellent survival of patients on this protocol suggests the possibility of a benefit that should be assessed in future studies...
  84. pmc Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice
    Javeed A Shah
    VRC, NIAID, 40 Convent Dr, Room 40 3512, NIH, Bethesda, MD 20892, USA
    J Exp Med 198:281-91. 2003
    ..Therefore, the combination of LACK antigen and CpG ODN adjuvant leads to the presence of CD11c+ DCs in the draining LN that are capable of vaccinating naive mice in the absence of further antigen or adjuvant...
  85. ncbi Statins as immunomodulators: comparison with interferon-beta 1b in MS
    O Neuhaus
    Department of Neurology, Multiple Sclerosis Research Group, Karl Franzens Universität, Graz, Austria
    Neurology 59:990-7. 2002
    ..In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)beta-1b...
  86. ncbi Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function
    George Miller
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 169:2875-85. 2002
    ..Our findings show that GM-CSF can have an important role in DC development and recruitment in vivo and has potential application to immunotherapy in recruiting massive numbers of DC with enhanced ability to activate effector cells...
  87. ncbi Adjuvant and immuno-suppressive effect of six monophthalates in a subcutaneous injection model with BALB/c mice
    S T Larsen
    National Institute of Occupational Health, Lersø Parkallé 105, 2100, Copenhagen, Denmark
    Toxicology 169:37-51. 2001
    ..No statistically significant immune modulating effect was seen with MBnP and MnBP...
  88. ncbi Airway inflammation and adjuvant effect after repeated airborne exposures to di-(2-ethylhexyl)phthalate and ovalbumin in BALB/c mice
    Søren Thor Larsen
    National Research Centre for the Working Environment, Copenhagen, Denmark
    Toxicology 235:119-29. 2007
    ..Furthermore, studies in mice have demonstrated an adjuvant effect from DEHP after parenteral administration with the model allergen ovalbumin (OVA)...
  89. ncbi Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival
    Thomas C Mitchell
    Institute for Cellular Therapeutics, University of Louisville School of Medicine, Louisville, Kentucky 40202, USA
    Ann N Y Acad Sci 975:114-31. 2002
    ..b>Immunologic adjuvants can initiate these signals in a process we designate adjuvant-induced survival (AIS)...
  90. pmc Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1249-58. 2006
    ..These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses...
  91. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ....
  92. ncbi Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle
    R K Gherardi
    Equipe mixte INSERM E 0011 Université Paris XII, France
    Brain 124:1821-31. 2001
    ....
  93. ncbi GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines
    Miguel Angel Perales
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytokines Cell Mol Ther 7:125-33. 2002
    ..These results have implications for understanding early events in the immune response to DNA vaccines, and provide a basis for development of new approaches to cancer vaccines, including the use of cytokine genes as adjuvants...
  94. ncbi The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination
    Xiaogang Du
    State Key Laboratory for Agro Biotechnology, Department of Microbiology and Immunology, College of Biological Science, China Agricultural University, Beijing 100094, China
    J Gene Med 9:136-46. 2007
    ..This approach may lead to an effective therapeutic vaccine for chronic hepatitis B virus (HBV) infection...
  95. ncbi Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses
    Arnaud Debin
    Biovector Therapeutics, Chemin du Chene Vert, BP 169, 31676 Labège, France
    Vaccine 20:2752-63. 2002
    ..These data demonstrate the high potential of SMBV for use as a nasal delivery system for sub-unit vaccines...
  96. ncbi Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide
    Mayda Gursel
    Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A Rm 3D10, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Leukoc Biol 71:813-20. 2002
    ..Thus, different types of CpG ODN have distinct and in some cases incompatible effects on the same cells, a finding with important implications for the therapeutic use of these agents...
  97. pmc The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells
    Anette Bauer
    Institute for Medical Microbiology, Technical University Munich, Trogerstrasse 9, D 81675 Munich, Germany
    Proc Natl Acad Sci U S A 103:10979-84. 2006
    ..IL-1, IL-7, and IL-15 primed T cells for survival even in the absence of Bim or Puma. Our data define interrelations and a Bim-independent pathway to activated T cell death...
  98. ncbi Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome
    I Jolanda M de Vries
    Department of Tumor Immunology, Radbond University Nijmegen Medical Center, Geert Grooteplein 26 28, 6500 HB Nijmegen, Netherlands
    J Clin Oncol 23:5779-87. 2005
    ..In this study, we investigated the predictive value of the presence or absence of antigen-specific T cells in biopsies from delayed-type hypersensitivity (DTH) sites...
  99. ncbi Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation
    Hitoshi Takayama
    Departments of Urology and Pathology KA, Osaka University Graduate School of Medicine, Suita, Japan
    J Urol 181:1894-900. 2009
    ..We investigated the correlation between tumor associated macrophages infiltrating bladder carcinoma in situ and the response to intravesical bacillus Calmette-Guerin therapy...
  100. ncbi Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
    Ai Ninomiya
    Laboratory of Influenza Viruses, Department of Virology 3, National Institute of Infectious Diseases, Gakuen 4 7 1, Musashi Murayama, Tokyo 208 0011, Japan
    Vaccine 25:3554-60. 2007
    ..Our study suggests that rgHK213/03 vaccine is still useful as a backup vaccine for recent H5N1 viruses and that if rgVNJP1203/04 vaccine is employed, more vaccine antigen would be necessary to induce sufficient immunity...
  101. ncbi Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract
    Megan T Sanders
    Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria, Australia
    Vaccine 27:2475-82. 2009
    ..Good protective responses can thus be achieved with only a single intranasal inoculation of influenza vaccine formulated with adjuvant, providing the vaccine can access sites of immune induction in the lower respiratory tract...

Research Grants66

  1. Developing Immunotherapeutics for Methamphetamine Abuse
    THOMAS RICHARD KOSTEN; Fiscal Year: 2010
    ..Orson and Kinsey have been working on the development of DMA vaccines. Our group's combined experience is ideally positioned to get a vaccine quickly into phase 1 human studies. ..
  2. Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect
    Wolfgang W Scholz; Fiscal Year: 2012
    ..The primary endpoint for this pivotal multicenter randomized trial is improvement in progression-free survival at one year. ..
  3. Near-infrared laser to replace chemical vaccine adjuvant
    Satoshi Kashiwagi; Fiscal Year: 2013
    ..The ultimate purpose of this is to replace a concurrent chemical or biological vaccine adjuvant. Although immunologic adjuvants are often essential for current vaccines, many licensed and development-stage adjuvants cause significant ..
  4. Therapeutic Synergy of Membrane-Anchored Cytokines, TLR Ligands &Ukrain
    Erica Bozeman; Fiscal Year: 2012
    ..abstract_text> ..
  5. Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine
    Ronald G Crystal; Fiscal Year: 2013
    ..Aim 4. Carry out a phase I trial to assess the safety nd preliminary measure of efficacy of the dAd5GNE vaccine in humans. ..
  6. CONSTRUCTION AND TESTING OF A TRIVALENT VACCINE AGAINST NEUROBLASTOMA ADMINISTERE
    Govind Ragupathi; Fiscal Year: 2012
    ..Establishment of new metastasis would no longer be possible so treatment with chemotherapy might result in long-term control of even metastatic neuroblastoma. ..
  7. OVERCOMING THE DEGRADING EFFECTS OF NICOTINE ON VACCINE USING TLR AGONISTS
    Mahyar Nouri-Shirazi; Fiscal Year: 2013
    ..We envision that such findings could be applied to further development of current and future vaccines. ..
  8. Development of Amygdala specific monoclonal Antibodies
    Andreas Kottmann; Fiscal Year: 2002
    ..In addition, we want to develop reagents to plastic changes of brain tissues in the context of inducible animal models with relevance to human psychiatric diseases. ..
  9. Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
    Richard Carvajal; Fiscal Year: 2009
    ..The establishment of new metastases would no longer be possible, so aggressive local therapies including surgery and radiation therapy might result in long-term control or potential cure of even metastatic sarcoma. ..
  10. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2002
    ..carcinoma will be treated with adjuvant 5FU and leucovorin and anti-Id 3Hl in combination with different immunologic adjuvants such as GS-21, GM-CSF or low-dose IL-2...
  11. T CELL IMMUNITY AND SYNTHETIC PEPTIDE AIDS VACCINES
    Amnon Altman; Fiscal Year: 1991
    ..The proposed studies could constitute a step towards the formulation of effective and highly immunogenic synthetic vaccines against AIDS and other infectious diseases...
  12. RESPIRATORY ANAPHYLAXIS TO INDUSTRIAL CHEMICALS
    MERYL KAROL; Fiscal Year: 1991
    ..normal breathing patterns and thus normal distribution of chemical in the respiratory tract, and no immunologic adjuvants are used to artificially stimulate an immune response...
  13. A Novel Immune Modulator/ Adjuvant for HIV Vaccines
    William Raschke; Fiscal Year: 2009
    ..The initial results which we plan to extend in this study, show the enhancement is not only due to greater immune responses but also a shift of the type of response to one better suited to protect against HIV. ..
  14. CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
    Philip Livingston; Fiscal Year: 1999
    ....
  15. T CELL ANTIGEN RECEPTOR AS A TARGET FOR IMMUNOTHERAPY
    Ronald Levy; Fiscal Year: 1999
    ..Cytokine hybrid protein molecules will also be produced. Several different immunologic adjuvants will be studied including SAF-1, QS-21 (a purified component of saponin) and the cytokine IL-12. 3...
  16. Chitosan-Zinc as an Immunological Adjuvant
    MITZI MARTINEZ MONTGOMERY; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATION: Products, such as improved adjuvants, that will enhance the immune response to poorly immunogenic antigens, should be widely received and commercially profitable. ..
  17. Novel Protein Adjuvant
    Andrew Heath; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  18. Intratumoral Dendritic Cells Plus Interleukin-2
    Pierre Triozzi; Fiscal Year: 2002
    ....
  19. SIMIAN VACCINE EVALUATION UNITS
    Mark Lewis; Fiscal Year: 2000
    ..include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as immunologic adjuvants and delivery vehicles...
  20. SIMIAN VACCINE EVALUATION UNITS
    Michael Murphey Corb; Fiscal Year: 1999
    ..include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as immunologic adjuvants and delivery vehicles...
  21. SIMIAN VACCINE EVALUATION UNITS
    William Morton; Fiscal Year: 1999
    ..include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as Immunologic adjuvants and delivery vehicles...
  22. REAGENT RESOURCE SUPPORT FOR AIDS VACCINE DEVELOPMENT
    Ronald Brown; Fiscal Year: 2000
    ..g., HIV-1, SIV) for distribution for use by DAIDS-supported investigators. 2- Acquire and characterize immunologic adjuvants, immunomodulators, and vaccine delivery systems for use in experimental HIV vaccine formulations...
  23. SIMIAN VACCINE EVALUATION UNITS
    Phillip Markham; Fiscal Year: 2000
    ..Vaccine strategies investigated will include nucleic acid vaccines, recombinant proteins, whole-killed and attenuated viral vaccines as well as immunologic adjuvants and antigen delivery systems.
  24. Immune Pathways as Prerequisites for Adjuvants' Efficacy
    George Hui; Fiscal Year: 2004
    ....
  25. Early Life Exposure to Microbial Products and Asthma
    Joel Kline; Fiscal Year: 2005
    ..Question 2A: What mediators promote immune tolerance induced by early life exposure to microbial products? Question 2B: What cells are responsible for immune tolerance induced by early life exposure to microbial products? ..
  26. Helminth-Induced Immune Tolerance in Asthma
    Joel Kline; Fiscal Year: 2005
    ..Although completion of the second Aim is almost certainly beyond the scope of this two-year developmental research grant, these studies will be continued and extended through an R01 grant application. ..
  27. Induction of Respiratory Tolerance By Mucosal CpG ODN
    Joel Kline; Fiscal Year: 2006
    ..Aim 2: To evaluate whether anti-inflammatory effects of airway mucosal exposure to CpG-ODN are mediated through regulatory T-lymphocytes. ..
  28. Reducing Transmission of Influenza by Face Masks
    ARNOLD MONTO; Fiscal Year: 2008
    ..Such a reduction could have a major public health impact during a pandemic. In the second year, the study can be expanded or modified based on findings in the first. ..
  29. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  30. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. [unreadable] [unreadable]..
  31. MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF
    Craig Slingluff; Fiscal Year: 2004
    ..abstract_text> ..
  32. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    ....
  33. Comparative Study of Influenza Vaccines in Adults
    ARNOLD MONTO; Fiscal Year: 2006
    ..Results will help to determine how the vaccine may be used as part of the strategy to combat influenza in varying situations. [unreadable] [unreadable]..
  34. Anthrax DNA vaccine for non-invasive immunization on skin
    Zhengrong Cui; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  35. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2009
    ....
  36. Combined TNFSF and TLR stimulation of HIV vaccines
    RICHARD KORNBLUTH; Fiscal Year: 2006
    ..In addition, this DNA vaccine approach may prove generally applicable for emerging infections and other diseases for which a potent vaccine is needed. ..
  37. VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES
    Craig Slingluff; Fiscal Year: 2004
    ....
  38. TNFSF APC activators for HIV Vaccines
    RICHARD KORNBLUTH; Fiscal Year: 2003
    ..Upon the completion of these feasibility studies, it will be clear if these concepts should be advanced into more extensive vaccine studies both for HIV and other pathogens. ..
  39. Case/Cleveland Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2004
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
  40. TRANSCUTANEOUS IMMUNIZATION FOR TETANUS BOOSTER
    Gregory Glenn; Fiscal Year: 2003
    ..Additionally, the Transcutaneous booster will decrease the risk of needle-sticks and related disease, and reduce personnel and equipment requirements related to tetanus immunization. ..
  41. Transcutaneous Immunization for an Anthrax Vaccine
    Gregory Glenn; Fiscal Year: 2005
    ....
  42. 2nd International Conference on Prostate Cancer Research
    David Lubaroff; Fiscal Year: 2002
    ..Selection of the travel awardees will be made by a subcommittee of the Organizing Committee and will be based upon the quality of the research contained in the submitted abstracts. ..
  43. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  44. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
    ..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
  45. Regulation of HIV-1 Preintegration Complexes (PICs)
    RICHARD KORNBLUTH; Fiscal Year: 2002
    ..New tools and concepts will be gained, and precise molecular targets for anti-HIV drug design will come into focus. ..
  46. Borrelia lipoproteins with the cerebral microcirculation
    Diego Cadavid; Fiscal Year: 2007
    ..2. Investigate whether Vspl enters BMEC. 3. Determine whether Vspl crosses BMEC barriers. 4. Identify the structural features that mediate the interaction of Vspl with BMEC. [unreadable] [unreadable]..
  47. Chemokine Potential in Cancer Immunotherapy
    Dean Johnston; Fiscal Year: 2002
    ..Chemokines that prove effective in these models could be directly translated to clinical trials under the direction of Dr. Jean-Claude Bystryn, the CoPI, at NYU Medical Center. ..
  48. Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
    Alan Cross; Fiscal Year: 2010
    ..Since inhibitors of sialidase are commercially available, these studies will provide the experimental rationale for testing a new therapeutic approach to the treatment of lung injury. ..
  49. SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
    Alan Cross; Fiscal Year: 2002
    ..These studies will define a new mechanism for a rapidly adaptable, temporally- restricted local response to inflammation. This proposal will provide new targets and additional approaches to the treatment of inflammation. ..
  50. Formulated Patch for Topical Influenza Vaccine
    Gregory Glenn; Fiscal Year: 2004
    ..Needle-free may also aid in the extension of use of a flu patch into the pediatric population where influenza immunization is now recommended by the ACIP and will be a subsequent goal of this development program. ..
  51. A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli
    Zhengrong Cui; Fiscal Year: 2008
    ..The same vaccine or its modified version can also be used in agricultural industries to vaccinate cattle. [unreadable] [unreadable] [unreadable]..
  52. Evaluation of Anti-endotoxin Vaccine for Human Use
    Alan Cross; Fiscal Year: 2006
    ..If successful, these studies will lead to phase II and Ill studies for the prevention and treatment of sepsis. ..
  53. Early events during infection with anthrax
    Alan Cross; Fiscal Year: 2006
    ..abstract_text> ..
  54. INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS
    Alan Cross; Fiscal Year: 2001
    ..The demonstration of a spectrum of responses to LPS in these studies may identify the earliest changes in cytokine responses that predict the development of sepsis. ..
  55. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  56. TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITY
    DANIEL HOFT; Fiscal Year: 2008
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
  57. Vaccines to Generate Neutralizing Anti-HIV Antibodies
    RICHARD KORNBLUTH; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  58. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2008
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  59. Molecular Determinants of Virulence Porcine Circovirus 2
    Steven Krakowka; Fiscal Year: 2007
    ..Collectively, these data will provide critical insight into pathogenic mechanisms of disease mediated by mammalian circoviruses and will provide key guidance for the future study of human circovirus pathogens. ..
  60. Mucosal Therapy for Autoimmunity
    David Pascual; Fiscal Year: 2008
    ..Studies in Specific Aim 3 will determine the responsible dendritic cell subset that supports regulatory T cell development. ..
  61. Enhancement of Tuberculosis Vaccine by Thymosin
    Cynthia Tuthill; Fiscal Year: 2003
    ..Findings that indicate superior performance to BCG vaccinated controls will provide the basis for further evaluations in the more sensitive guinea pig model of infection. ..
  62. IMMUNE RESPONSES TO SMALL INTESTINAL SUBMUCOSA
    DENNIS METZGER; Fiscal Year: 2001
    ..The results will provide important insight into the mechanisms responsible for successful xenogeneic transplantation and could lead to targeted cytokine therapies to prevent tissue rejection. ..
  63. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2006
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..
  64. Biodefense vaccine for pandemic influenza
    Lawrence Smith; Fiscal Year: 2005
    ..FINAL MILESTONE 3: Completion of Aim 2 and completion of IND ..
  65. MOLECULAR MECHANISMS OF CONDITIONED TASTE AVERSION
    THOMAS HOUPT; Fiscal Year: 2004
    ..These experiments will contribute to an understanding of the neural pathways and molecular mechanisms underlying changes in food preferences that occur in eating disorders such as obesity and anorexia nervosa. ..